Description
D058-1283 is a CD45 monoclonal antibody specific for non-human primate leucocytes. It was developed using Rhesus peripheral whole blood as the immunogen. It does not cross-react with human leucocytes. This antibody reacts with baboon, Rhesus and Cynomolgus Macaque leucocytes in a similar pattern to CD45 binding to leukocyte common antigen (LCA) on human cells. Immunophenotypic analysis shows that D058-1283 binds to lymphocytes, monocytes and granulocytes of non-human primate blood samples. This antibody is able to block the binding of monoclonal antibody TÜ116; a reported anti-human CD45 antibody that cross-reacts with nonhuman primate leucocytes. In Western blot analysis, the D058-1283 antibody identifies a 180-200 kDa band.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
3. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
4. An isotype control should be used at the same concentration as the antibody of interest.
5. Researchers should determine the optimal concentration of this reagent for their individual applications.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. Please observe the following precautions: Absorption of visible light can significantly alter the energy transfer occurring in any tandem fluorochrome conjugate; therefore, we recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to prevent exposure of conjugated reagents, including cells stained with those reagents, to room illumination.
8. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
9. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
10. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
11. Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
